A share price of Rocket Pharmaceuticals Inc [RCKT] is currently trading at $3.47, up 1.46%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The RCKT shares have gain 9.12% over the last week, with a monthly amount glided 9.81%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Rocket Pharmaceuticals Inc [NASDAQ: RCKT] stock has seen the most recent analyst activity on August 20, 2025, when BofA Securities upgraded its rating to a Buy but kept the price target unchanged to $10 for it. Previously, BofA Securities downgraded its rating to Neutral on July 25, 2025, and kept the price target unchanged to $4. On May 30, 2025, downgrade downgraded it’s rating to In-line but maintained its price target of $5 on the stock. Morgan Stanley downgraded its rating to a Equal-Weight but stick to its price target of $7 on May 28, 2025. Leerink Partners downgraded its rating to a Market Perform but $8 remained the price target by the analyst firm on May 28, 2025. JP Morgan downgraded its rating to Neutral for this stock on May 28, 2025. In a note dated May 28, 2025, Jefferies downgraded an Hold rating on this stock but restated the target price of $2.50.
Rocket Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $2.19 and $18.89. Currently, Wall Street analysts expect the stock to reach $3.83 within the next 12 months. Rocket Pharmaceuticals Inc [NASDAQ: RCKT] shares were valued at $3.47 at the most recent close of the market. An investor can expect a potential return of 10.37% based on the average RCKT price forecast.
Analyzing the RCKT fundamentals
Gross Profit Margin for this corporation currently stands at -0.36% with Operating Profit Margin at -29.14%, Pretax Profit Margin comes in at -28.01%, and Net Profit Margin reading is -28.01%. To continue investigating profitability, this company’s Return on Assets is posted at -0.61, Equity is -0.66 and Total Capital is -0.71. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Rocket Pharmaceuticals Inc [NASDAQ:RCKT] is 6.39. Also, the Quick Ratio is 6.39, while the Cash Ratio stands at 0.76.
Transactions by insiders
Recent insider trading involved Bjork Elisabeth, Director, that happened on Aug 27 ’25 when 10000.0 shares were purchased. Militello John completed a deal on Aug 18 ’25 to sell 699.0 shares. Meanwhile, Militello John sold 361.0 shares on Aug 19 ’25.
